Sodium butyrate increases expression of the coxsackie and adenovirus receptor in colon cancer cells.
Histone deacetylase inhibitors (HDACI), e.g., sodium butyrate (NaB), have been suggested to upregulate the coxsackie and adenovirus receptor (CAR). Its impact on CAR in colon carcinomas, however, is poorly understood. NaB treatment of colon cancer cells increased CAR expression preferentially in cell lines with low basic CAR levels. These findings suggest that downregulation of CAR gene expression is mediated by transcriptional regulation and that activation of the CAR gene promoter is modulated by histone acetylation. The employment of HDACI may, therefore, represent a promising approach for improving adenovirus-based therapies of colon cancers with low CAR expression levels.
Department of Internal Medicine, Divisions of Gastroenterology and Hepatology, Charité Medical School-Campus Virchow, Berlin, Germany.
Katrin
K
Küster
Carsten
C
Grötzinger
Annika
A
Koschel
Andreas
A
Fischer
Bertram
B
Wiedenmann
Mario
M
Anders
D000818:Animals; D002087:Butyrates / Q000494:pharmacology*; D016466:CHO Cells; D018938:Caco-2 Cells; D002454:Cell Differentiation; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D006224:Cricetinae; D003412:Cricetulus; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D012333:RNA, Messenger / Q000032:analysis; D011991:Receptors, Virus / Q000187:drug effects* / Q000235:genetics
D002087:Butyrates; C568771:CLMP protein, human; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D056572:Histone Deacetylase Inhibitors; D012333:RNA, Messenger; D011991:Receptors, Virus